1. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.
MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. A, fluorescence observed on HPAC and A375 cell lines by flow cytometry following staining with an anti–PD-L1 (filled) antibody or an isotype control antibody (dotted). B, HPAC tumor volumes (mm3) in NOD/SCID mice following coimplantation of primary human T cells and administration of MEDI4736 i.p. at 5, 1, 0.1, and 0.01 mg/kg twice per week for 3 weeks as indicated. C, A375 tumor volumes (mm3) in NOD/SCID mice following coimplantation of primary human T cells and administration of MEDI4736 i.p. at 5, 1, and 0.1 mg/kg twice per week for 3 weeks as indicated. D, A375 tumor volumes (mm3) in NOD/SCID mice without coimplantation of primary human T cells and administration of MEDI4736 i.p. at 1 and 0.1 mg/kg twice per week for 3 weeks as indicated. *, P ≤ 0.05 as determined by a Mann–Whitney rank sum test.
Ross Stewart et al. Cancer Immunol Res 2015;3:
©2015 by American Association for Cancer Research